多药耐药逆转剂增加去甲柔红霉素对正常造血干细胞的毒性

Multidrug resistance modifier MS-209 increase the cytotoxicity of idarubicin to normal hemapoietic precursor cells

目的 探讨多药耐药逆转剂是否增加化疗药物对正常造血干细胞的毒性。方法 采用甲基纤维素半固体培养方法，培养正常人粒细胞－ 巨噬细胞克隆形成单位（ＣＦＵ－ＧＭ）。测定去甲柔红霉素对ＣＦＵ－ＧＭ 的抑制率。将多药耐药逆转剂ＭＳ－２０９及去甲柔红霉素与骨髓细胞共同短期作用后，了解去甲柔红霉素对ＣＦＵ－ＧＭ 抑制率的变化。结果 去甲柔红霉素对ＣＦＵ－ＧＭ 的平均抑制率为２９．６％ ，在ＭＳ－２０９作用下，其抑制率增加为４３．４％ ，有显著性差异（Ｐ＜ ０．０５）。结论 多药耐药逆转剂ＭＳ－２０９ 增加了化疗药物对造血干细胞的毒性。提示该类药物在临床应用中可能对造血系统具有一定副作用。

Objective To explore the effect of multidrug resistance(MDR)modifier on the cytotoxicity of idarubicin to normal hematoietic precursor cells.Methods Detecting the inhibiting rate of granulocyto macrophage colony forming unit(CFU GM)by idarubicin with and without new MDR modifier MS 209.Results The average inhibiting rate of idarubicin to CFU GM was 29 6%,and received to 43 4% when co incubated with MS 209.Conclusion New MDR modifier MS 209 increased the cytotoxicity of chemotherapy drug idarubicin to normal hemapoietic precursor cells.when such new MDR modifiers were used to reversing the MDR of tumor cells with chemotherapy drugs,the side effects to normal cells might be given more attention.[